Precision Medicine Accelerates as AI and Genomics Reshape Healthcare Investment
Personalized healthcare has moved past the conceptual phase into commercial viability, driven by the collapsing cost of genomic sequencing and the integration of artificial intelligence. The article examines how this convergence is forcing biopharma companies and investors to abandon the traditional "blockbuster" drug model in favor of targeted therapies and predictive diagnostics, while highlighting the data infrastructure challenges that remain.